{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:12:43Z","timestamp":1789945963805,"version":"4.0.1"},"reference-count":51,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,8,1]]},"abstract":"<jats:p>OBJECTIVE. Erythropoietin has been shown to be protective against hypoxic-ischemic and inflammatory injuries in cell culture, animal models of brain injury, and clinical trials of adult humans. The rationale for our study was that early administration of high-dose recombinant human erythropoietin may reduce perinatal brain injury (intraventricular hemorrhage and periventricular leukomalacia) in very preterm infants and improve neurodevelopmental outcome. We investigated whether administration of high-dose recombinant human erythropoietin to very preterm infants shortly after birth and subsequently during the first 2 days is safe in terms of short-term outcome.<\/jats:p>\n               <jats:p>METHODS. This was a randomized, double-masked, single-center trial with a 2:1 allocation in favor of recombinant human erythropoietin. Preterm infants (gestational age: 24 to 31 weeks) were given recombinant human erythropoietin or NaCl 0.9% intravenously 3, 12 to 18, and 36 to 42 hours after birth.<\/jats:p>\n               <jats:p>RESULTS. The percentage of infants who survived without brain injury or retinopathy was 53% in the recombinant human erythropoietin group and 60% in the placebo group. There were no relevant differences regarding short-term outcomes such as intraventricular hemorrhage, retinopathy, sepsis, necrotizing enterocolitis, and bronchopulmonary dysplasia. For 5 infants who were in the recombinant human erythropoietin group and had a gestational age of &amp;lt;26 weeks, withdrawal of intensive care was decided (3 of 5 with severe bilateral intraventricular hemorrhage, 2 of 5 with pulmonary insufficiency); no infant of the control group died. Recombinant human erythropoietin treatment did not result in significant differences in blood pressure, cerebral oxygenation, hemoglobin, leukocyte, and platelet count.<\/jats:p>\n               <jats:p>CONCLUSIONS. No significant adverse effects of early high-dose recombinant human erythropoietin treatment in very preterm infants were identified. These results enable us to embark on a large multicenter trial with the aim of determining whether early high-dose administration of recombinant human erythropoietin to very preterm infants improves neurodevelopmental outcome at 24 months' and 5 years' corrected age.<\/jats:p>","DOI":"10.1542\/peds.2007-2591","type":"journal-article","created":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T13:38:30Z","timestamp":1217597910000},"page":"375-382","source":"Crossref","is-referenced-by-count":134,"title":["An Approach to Using Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants"],"prefix":"10.1542","volume":"122","author":[{"given":"Jean-Claude","family":"Fauche\u0300re","sequence":"first","affiliation":[{"name":"Clinic of Neonatology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Dame","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Campus Virchow-Klinikum, Charite\u0301-Universita\u0308tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Vonthein","sequence":"additional","affiliation":[{"name":"Department of Medical Biometry, University of Tu\u0308bingen, Tu\u0308bingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Koller","sequence":"additional","affiliation":[{"name":"Clinic of Neonatology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Arri","sequence":"additional","affiliation":[{"name":"Clinic of Neonatology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wolf","sequence":"additional","affiliation":[{"name":"Clinic of Neonatology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Ulrich","family":"Bucher","sequence":"additional","affiliation":[{"name":"Clinic of Neonatology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2008,8,1]]},"reference":[{"key":"2021120906004766900_R1","doi-asserted-by":"crossref","unstructured":"Marlow N, Wolke D, Bracewell MA, Samara M, for the EPICure Study Group. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med.\u20082005;352(1):9\u201319","DOI":"10.1056\/NEJMoa041367"},{"key":"2021120906004766900_R2","doi-asserted-by":"crossref","unstructured":"Bucher HU, Killer C, Ochsner Y, Vaihinger S, Fauchere JC. Growth, developmental milestones and health problems in the first 2 years in very preterm infants compared with term infants: a population based study. Eur J Pediatr.\u20082002;161(3):151\u2013156","DOI":"10.1007\/s00431-001-0898-0"},{"key":"2021120906004766900_R3","doi-asserted-by":"crossref","unstructured":"Winter S, Autry A, Boyle C, Yeargin-Allsopp M. Trends in the prevalence of cerebral palsy in a population-based study. Pediatrics.\u20082002;110(6):1220\u20131225","DOI":"10.1542\/peds.110.6.1220"},{"key":"2021120906004766900_R4","doi-asserted-by":"crossref","unstructured":"Meadow W, Lee G, Lin K, Lantos J. Changes in mortality for extremely low birth weight infants in the 1990s: implications for treatment decisions and resource use. Pediatrics.\u20082004;113(5):1223\u20131229","DOI":"10.1542\/peds.113.5.1223"},{"key":"2021120906004766900_R5","doi-asserted-by":"crossref","unstructured":"Dame C, Juul S, Christensen RD. The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biol Neonate.\u20082001;79(3\u20134):228\u2013235","DOI":"10.1159\/000047097"},{"key":"2021120906004766900_R6","doi-asserted-by":"crossref","unstructured":"Gassmann M, Heinicke K, Soliz J, Ogunshola OO. Non-erythroid functions of erythropoietin. Adv Exp Med Biol.\u20082003;543:323\u2013330","DOI":"10.1007\/978-1-4419-8997-0_22"},{"key":"2021120906004766900_R7","doi-asserted-by":"crossref","unstructured":"Jelkmann W, Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol.\u20082004;83(11):673\u2013686","DOI":"10.1007\/s00277-004-0911-6"},{"key":"2021120906004766900_R8","doi-asserted-by":"crossref","unstructured":"Fandrey J. A cordial affair: erythropoietin and cardioprotection. Cardiovasc Res.\u20082006;72(1):1\u20132","DOI":"10.1016\/j.cardiores.2006.07.024"},{"key":"2021120906004766900_R9","doi-asserted-by":"crossref","unstructured":"Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA.\u20082005;293(1):90\u201395","DOI":"10.1001\/jama.293.1.90"},{"key":"2021120906004766900_R10","doi-asserted-by":"crossref","unstructured":"Noguchi CT, Asavaritikrai P, Teng R, Jia Y. Role of erythropoietin in the brain. Crit Rev Oncol Hematol.\u20082007;64(2):159\u2013171","DOI":"10.1016\/j.critrevonc.2007.03.001"},{"key":"2021120906004766900_R11","doi-asserted-by":"crossref","unstructured":"Ehrenreich H, Fischer B, Norra C, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain.\u20082007;130(Pt 10):2577\u20132588","DOI":"10.1093\/brain\/awm203"},{"key":"2021120906004766900_R12","doi-asserted-by":"crossref","unstructured":"Juul S, Felderhoff-Mueser U. Epo and other hematopoietic factors. Semin Fetal Neonatal Med.\u20082007;12(4):250\u2013258","DOI":"10.1016\/j.siny.2007.01.015"},{"key":"2021120906004766900_R13","doi-asserted-by":"crossref","unstructured":"Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA.\u20082004;101(41):14907\u201314912","DOI":"10.1073\/pnas.0406491101"},{"key":"2021120906004766900_R14","doi-asserted-by":"crossref","unstructured":"Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med.\u20082002;8(8):495\u2013505","DOI":"10.1007\/BF03402029"},{"key":"2021120906004766900_R15","doi-asserted-by":"crossref","unstructured":"Ehrenreich H, Hinze-Selch D, Stawicki S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry.\u20082007;12(2):206\u2013220","DOI":"10.1038\/sj.mp.4001907"},{"key":"2021120906004766900_R16","doi-asserted-by":"crossref","unstructured":"Maier RF, Obladen M, Muller-Hansen I, et al. Early treatment with erythropoietin beta ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. J Pediatr.\u20082002;141(1):8\u201315","DOI":"10.1067\/mpd.2002.124309"},{"key":"2021120906004766900_R17","doi-asserted-by":"crossref","unstructured":"Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and\/or low birth weight infants. Cochrane Database Syst Rev.\u20082006;(3):CD004865","DOI":"10.1002\/14651858.CD004865.pub2"},{"key":"2021120906004766900_R18","doi-asserted-by":"crossref","unstructured":"Ohlsson A, Aher S. Early erythropoietin for preventing red blood cell transfusion in preterm and\/or low birth weight infants. Cochrane Database Syst Rev.\u20082006;(3):CD004863. DOI: 10.1002\/14651858.CD004863.pub2.","DOI":"10.1002\/14651858.CD004863.pub2"},{"key":"2021120906004766900_R19","doi-asserted-by":"crossref","unstructured":"Newton NR, Leonard CH, Piecuch RE, Phibbs RH. Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy. J Perinatol.\u20081999;19(6 pt 1):403\u2013406","DOI":"10.1038\/sj.jp.7200244"},{"key":"2021120906004766900_R20","doi-asserted-by":"crossref","unstructured":"Ohls RK, Ehrenkranz RA, Das A, et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics.\u20082004;114(5):1287\u20131291","DOI":"10.1542\/peds.2003-1129-L"},{"key":"2021120906004766900_R21","doi-asserted-by":"crossref","unstructured":"Bierer R, Peceny MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics.\u20082006;118(3). Available at: www.pediatrics.org\/cgi\/content\/full\/118\/3\/e635","DOI":"10.1542\/peds.2005-3186"},{"key":"2021120906004766900_R22","doi-asserted-by":"crossref","unstructured":"Chin K, Yu X, Beleslin-Cokic B, et al. Production and processing of erythropoietin receptor transcripts in brain. Brain Res Mol Brain Res.\u20082000;81(1\u20132):29\u201342","DOI":"10.1016\/S0169-328X(00)00157-1"},{"key":"2021120906004766900_R23","doi-asserted-by":"crossref","unstructured":"Spandou E, Papoutsopoulou S, Soubasi V, et al. Hypoxia-ischemia affects erythropoietin and erythropoietin receptor expression pattern in the neonatal rat brain. Brain Res.\u20082004;1021(2):167\u2013172","DOI":"10.1016\/j.brainres.2004.06.057"},{"key":"2021120906004766900_R24","doi-asserted-by":"crossref","unstructured":"Tsai PT, Ohab JJ, Kertesz N, et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci.\u20082006;26(4):1269\u20131274","DOI":"10.1523\/JNEUROSCI.4480-05.2006"},{"key":"2021120906004766900_R25","doi-asserted-by":"crossref","unstructured":"Chikuma M, Masuda S, Kobayashi T, Nagao M, Sasaki R. Tissue-specific regulation of erythropoietin production in the murine kidney, brain, and uterus. Am J Physiol Endocrinol Metab.\u20082000;279(6):E1242\u2013E1248","DOI":"10.1152\/ajpendo.2000.279.6.E1242"},{"key":"2021120906004766900_R26","doi-asserted-by":"crossref","unstructured":"Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA.\u20082000;97(19):10526\u201310531","DOI":"10.1073\/pnas.97.19.10526"},{"key":"2021120906004766900_R27","doi-asserted-by":"crossref","unstructured":"Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke.\u20082004;35(7):1732\u20131737","DOI":"10.1161\/01.STR.0000132196.49028.a4"},{"key":"2021120906004766900_R28","doi-asserted-by":"crossref","unstructured":"Parry G, Tucker J, Tarnow-Mordi W. CRIB II: an update of the clinical risk index for babies score. Lancet.\u20082003;361(9371):1789\u20131791","DOI":"10.1016\/S0140-6736(03)13397-1"},{"key":"2021120906004766900_R29","doi-asserted-by":"crossref","unstructured":"Ment LR, Bada HS, Barnes P, et al. Practice parameter: neuroimaging of the neonate\u2014report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology.\u20082002;58(12):1726\u20131738","DOI":"10.1212\/WNL.58.12.1726"},{"key":"2021120906004766900_R30","doi-asserted-by":"crossref","unstructured":"De Vries LS, Van Haastert IL, Rademaker KJ, Koopman C, Groenendaal F. Ultrasound abnormalities preceding cerebral palsy in high-risk preterm infants. J Pediatr.\u20082004;144(6):815\u2013820","DOI":"10.1016\/j.jpeds.2004.03.034"},{"key":"2021120906004766900_R31","doi-asserted-by":"crossref","unstructured":"International Committee for the Classification of the Late Stages of Retinopathy of Prematurity. An international classification of retinopathy of prematurity: II\u2014the classification of retinal detachment. Arch Ophthalmol.\u20081987;105(7):906\u2013912","DOI":"10.1001\/archopht.1987.01060070042025"},{"key":"2021120906004766900_R32","doi-asserted-by":"crossref","unstructured":"Goodman SN. Toward evidence-based medical statistics: 2\u2014the Bayes factor. Ann Intern Med.\u20081999;130(12):1005\u20131013","DOI":"10.7326\/0003-4819-130-12-199906150-00019"},{"key":"2021120906004766900_R33","doi-asserted-by":"crossref","unstructured":"Fahnenstich H, Dame C, Allera A, Kowalewski S. Biochemical monitoring of fetal distress with serum-immunoreactive erythropoietin. J Perinat Med.\u20081996;24(1):85\u201391","DOI":"10.1515\/jpme.1996.24.1.85"},{"key":"2021120906004766900_R34","unstructured":"Wolf M, Egli K, Karen T, Barbaro R, Bauschatz A, Bucher H. Effects of Erythropoietin on Cerebral Blood Circulation Measured by Near-infrared Spectroscopy in Preterm Neonates. Barcelona, Spain: European Academy of Paediatrics; 2006:125"},{"key":"2021120906004766900_R35","doi-asserted-by":"crossref","unstructured":"Vanhaesebrouck P, Allegaert K, Bottu J, et al. The EPIBEL Study: outcomes to discharge from hospital for extremely preterm infants in Belgium. Pediatrics.\u20082004;114(3):663\u2013675","DOI":"10.1542\/peds.2003-0903-L"},{"key":"2021120906004766900_R36","doi-asserted-by":"crossref","unstructured":"Markestad T, Kaaresen PI, Ronnestad A, et al. Early death, morbidity, and need of treatment among extremely premature infants. Pediatrics.\u20082005;115(5):1289\u20131298","DOI":"10.1542\/peds.2004-1482"},{"key":"2021120906004766900_R37","doi-asserted-by":"crossref","unstructured":"Mikkola K, Ritari N, Tommiska V, et al. Neurodevelopmental outcome at 5 years of age of a national cohort of extremely low birth weight infants who were born in 1996\u20131997. Pediatrics.\u20082005;116(6):1391\u20131400","DOI":"10.1542\/peds.2005-0171"},{"key":"2021120906004766900_R38","doi-asserted-by":"crossref","unstructured":"Costeloe K, Hennessy E, Gibson AT, Marlow N, Wilkinson AR, for the EPICure Study Group. The EPICure Study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics.\u20082000;106(4):659\u2013671","DOI":"10.1542\/peds.106.4.659"},{"key":"2021120906004766900_R39","doi-asserted-by":"crossref","unstructured":"Aydin A, Genc K, Akhisaroglu M, Yorukoglu K, Gokmen N, Gonullu E. Erythropoietin exerts neuroprotective effect in neonatal rat model of hypoxic-ischemic brain injury. Brain Dev.\u20082003;25(7):494\u2013498","DOI":"10.1016\/S0387-7604(03)00039-1"},{"key":"2021120906004766900_R40","doi-asserted-by":"crossref","unstructured":"Juul SE, McPherson RJ, Farrell FX, Jolliffe L, Ness DJ, Gleason CA. Erythropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate.\u20082004;85(2):138\u2013144","DOI":"10.1159\/000074970"},{"key":"2021120906004766900_R41","doi-asserted-by":"crossref","unstructured":"Sola A, Wen TC, Hamrick SE, Ferriero DM. Potential for protection and repair following injury to the developing brain: a role for erythropoietin?Pediatr Res.\u20082005;57(5 pt 2):110R\u2013117R","DOI":"10.1203\/01.PDR.0000159571.50758.39"},{"key":"2021120906004766900_R42","doi-asserted-by":"crossref","unstructured":"Kellert BA, McPherson RJ, Juul SE. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr Res.\u20082007;61(4):451\u2013455","DOI":"10.1203\/pdr.0b013e3180332cec"},{"key":"2021120906004766900_R43","doi-asserted-by":"crossref","unstructured":"Statler PA, McPherson RJ, Bauer LA, Kellert BA, Juul SE. Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res.\u20082007;61(6):671\u2013675","DOI":"10.1203\/pdr.0b013e31805341dc"},{"key":"2021120906004766900_R44","doi-asserted-by":"crossref","unstructured":"Wang Y, Zhang ZG, Rhodes K, et al. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol.\u20082007;151(8):1377\u20131384","DOI":"10.1038\/sj.bjp.0707285"},{"key":"2021120906004766900_R45","doi-asserted-by":"crossref","unstructured":"Weber A, Dzietko M, Berns M, et al. Neuronal damage after moderate hypoxia and erythropoietin. Neurobiol Dis.\u20082005;20(2):594\u2013600","DOI":"10.1016\/j.nbd.2005.04.016"},{"key":"2021120906004766900_R46","doi-asserted-by":"crossref","unstructured":"Xenocostas A, Cheung WK, Farrell F, et al. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol.\u20082005;61(3):189\u2013195","DOI":"10.1007\/s00228-005-0896-7"},{"key":"2021120906004766900_R47","doi-asserted-by":"crossref","unstructured":"Bu\u0308hrer C, Felderhoff-Mueser U, Wellmann S. Erythropoietin and ischemic conditioning: why two good things may be bad. Acta Paediatr.\u20082007;96(6):787\u2013789","DOI":"10.1111\/j.1651-2227.2007.00335.x"},{"key":"2021120906004766900_R48","doi-asserted-by":"crossref","unstructured":"Liu ZY, Chin K, Noguchi CT. Tissue specific expression of human erythropoietin receptor in transgenic mice. Dev Biol.\u20081994;166(1):159\u2013169","DOI":"10.1006\/dbio.1994.1304"},{"key":"2021120906004766900_R49","doi-asserted-by":"crossref","unstructured":"Plateel M, Teissier E, Cecchelli R. Hypoxia dramatically increases the nonspecific transport of blood-borne proteins to the brain. J Neurochem.\u20081997;68(2):874\u2013877","DOI":"10.1046\/j.1471-4159.1997.68020874.x"},{"key":"2021120906004766900_R50","doi-asserted-by":"crossref","unstructured":"Ehrenreich H, Hasselblatt M, Knerlich F, et al. A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain. Proc Natl Acad Sci USA.\u20082005;102(3):862\u2013867","DOI":"10.1073\/pnas.0406008102"},{"key":"2021120906004766900_R51","doi-asserted-by":"crossref","unstructured":"Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood.\u20082004;104(7):2073\u20132080","DOI":"10.1182\/blood-2004-02-0744"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/122\/2\/375\/1034514\/zpe00808000375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/122\/2\/375\/1034514\/zpe00808000375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:04:15Z","timestamp":1639094655000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/122\/2\/375\/73099\/An-Approach-to-Using-Recombinant-Erythropoietin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,1]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2008,8,1]]},"published-print":{"date-parts":[[2008,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-2591","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,1]]}}}